CureLab Oncology and the American Eurasian Cancer Alliance Partner to Fight Ovarian Cancer

BOSTON and PHILADELPHIA—January 31, 2022: CureLab Oncology,a clinical-stage biotech company, and the American Eurasian Cancer Alliance (AECA), have partnered to expand research and to fast-track next-generation therapies for ovarian cancer in Eurasia. The alliance aims to accelerate the clinical trials of CureLab Oncology’s Elenagen™, an experimental DNA therapy, by leveraging the broad reach and influence of the AECA in the region.

Since its inception in 2001, the AECA has implemented its vision of decreasing the burden of cancer in U.S. and Eurasian populations through strategic partnerships and programs that promote cancer research and enhance cancer control in the region. AECA’s reach extends across the Russian Federation, Central Asia (Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan), Central Europe (Ukraine, Moldova, Belarus), the Baltics (Lithuania, Latvia, Estonia), and Caucasia (Armenia, Georgia, Azerbaijan).

In Belarus, for example, the AECA and CureLab Oncology have already teamed to help launch the International Gynecologic Cancer Society (IGCS) program within the country. CureLab’s ongoing clinical research studies of Elenagen therapy at the N.N. Alexandrov National Cancer Centre of Belarus have demonstrated encouraging preliminary results in triple-negative breast cancer and platinum-resistant ovarian cancer patients.

“We want to build on our program in Belarus and bring the fight against ovarian cancer to more countries in the region,” said Alexander Shneider, Ph.D., CEO of CureLab Oncology. “The AECA’s commitment to strengthening global cancer research, promoting research training and education, and translating research into policy and programs will enable us to achieve that goal. Importantly, this is a two-way highway—if not a Möbius strip. An invention made by a team of American, Israeli, and Italian scientists came to Russia and Belarus for pre-clinical and early-stage clinical development, and now we are bringing it back to the United State for phase II clinical trials.”

“For decades, AECA has been on the cutting edge of scientific and technological oncology advancements, and we’re thrilled to continue this important endeavor with CureLab Oncology,” said Dr. Sophia Michaelson, executive director of the American Eurasian Cancer Alliance.